Skip to content
type1.science

Vertex VX-264 (device-encapsulated stem-cell islets)

Vertex Pharmaceuticals

A clear lesson in what doesn't work yet.

Vertex's "cure without immunosuppression" candidate: the same stem-cell-derived islets as zimislecel/VX-880, sealed inside an implantable immunoprotective device so no anti-rejection drugs are needed. In its Phase 1/2 trial the device proved safe but the cells did not produce enough insulin (C-peptide) to help, and Vertex discontinued it in March 2025 — a real-world illustration of the central encapsulation problem: protecting cells from the immune system also starves them of oxygen and triggers fibrosis.

DiscontinuedEarly evidencestem-cellisletencapsulationdeviceimmunoprotectionimmunosuppression-freeallogeneicdiscontinuedcure-candidate

The scorecard

Immunosuppression-free90

The entire point — and its one success: the device was designed to need zero systemic immunosuppression, and the trial confirmed it was given without anti-rejection drugs.

Insulin independence5

Failed: at Day 90 the encapsulated cells did not raise C-peptide to clinically meaningful levels, so no participant approached insulin independence.

Durability5

The core unsolved problem — oxygen/nutrient diffusion limits and fibrotic overgrowth appear to have prevented durable cell survival inside the device; explant analysis is ongoing.

Low invasiveness30

Requires surgical implantation under general anesthesia behind the abdominal-wall muscles — more invasive than the simple vein infusion used for the same cells without a device.

Eligibility breadth50

If it had worked, avoiding immunosuppression would have broadened access well beyond infusion-based islet therapy; trial enrolled adults 18–65 with T1D for at least 5 years.

Maturity5

Discontinued in March 2025 after a failed Phase 1/2 efficacy readout; no longer in active clinical development in this form.

The full picture

VX-264 was Vertex's attempt at the field's holy grail: a cell-based cure for type 1 diabetes that needs no lifelong anti-rejection drugs. It used the same stem-cell-derived, fully differentiated islet cells as Vertex's lead therapy zimislecel (VX-880), but instead of infusing them into the liver, it sealed them inside a proprietary implantable device.1 The device — a "channel array" built from two semipermeable polyvinylidene-fluoride membranes — is meant to let glucose, oxygen, nutrients and insulin pass through while physically blocking immune cells from reaching and destroying the islets.2 If it worked, recipients would make their own insulin again without the immunosuppression that makes infusion-based islet therapy too risky for most people.1

The approach. Allogeneic (donor-independent, lab-grown) islets are loaded into the device, which is implanted in a surgical procedure under general anesthesia, positioned behind the muscles of the abdominal wall.3 No immunosuppressive drugs are given — the device alone is supposed to protect the cells.1 Because the device is removable, the therapy is in principle reversible, a safety advantage over a permanent infusion.

Clinical evidence. VX-264 was tested in a Phase 1/2 trial (NCT05791201), a sequential multi-part study in adults aged 18–65 who had lived with T1D for at least five years.4 The primary efficacy endpoint was the change in peak C-peptide (a direct marker of the body's own insulin production) during a mixed-meal test, at Day 90.4 In March 2025 Vertex reported that, while VX-264 was generally safe and well tolerated, it did not meet the efficacy endpoint: increases in C-peptide were not seen at the levels needed to deliver benefit.5 Vertex discontinued the program and announced it would analyze the explanted devices to understand why.56

Why this matters — and the honest lesson. The failure is especially informative because the cells themselves are not the problem. The identical islets, infused into the liver with immunosuppression as zimislecel, produced insulin independence in 10 of 12 participants (83%) at one year in a parallel trial.7 So the device is the variable that failed — a textbook example of the central encapsulation challenge: a membrane tight enough to block immune attack is also a barrier to oxygen and nutrients, and the body responds to any implant with a foreign-body reaction and fibrotic scar tissue that further chokes off diffusion.2 Encapsulated islets sit far from blood vessels, and oxygen shortage (hypoxia) plus pericapsular fibrosis have repeatedly limited durable cell survival across the field's device programs.2 VX-264 appears to have hit exactly this wall.

Eligibility, safety, durability. Eligibility was limited to the trial cohort; the therapy was never approved or marketed anywhere.4 On the positive side, the device was safe and well tolerated with no immunosuppression burden.5 On durability, the decisive shortfall was that protected cells did not engraft and function well enough to matter — the opposite of durable.5

What's coming. VX-264 in its tested form is over.5 But the strategy is very much alive: Vertex and others continue to pursue immunosuppression-free cures through better-vascularized or oxygen-supplying devices and through gene-edited "hypoimmune" islets that evade rejection without any device at all.8 Watch the explant analyses from VX-264 (expected to sharpen exactly which failure mode dominated) and the next generation of encapsulation and immune-evasion approaches that aim to keep the immunosuppression-free promise while finally solving cell survival.8

References

  1. Vertex Pharmaceuticals. Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes. Vertex Newsroom (2022). https://news.vrtx.com/news-releases/news-release-details/vertex-announces-fda-clearance-investigational-new-drug ↩ ↩2 ↩3

  2. Aghazadeh Y, et al. Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects. BioDrugs / PMC (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC11906537/ ↩ ↩2 ↩3

  3. Hatcher S. Vertex halts development of diabetes cell therapy after trial failure. Clinical Trials Arena (2025). https://www.clinicaltrialsarena.com/news/vertex-halts-development-of-diabetes-cell-therapy-after-trial-failure/ ↩

  4. Vertex Pharmaceuticals. A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes. ClinicalTrials.gov NCT05791201 (2023). https://clinicaltrials.gov/study/NCT05791201 ↩ ↩2 ↩3

  5. Vertex Pharmaceuticals. Vertex Announces Program Updates for Type 1 Diabetes Portfolio. Vertex Investors (28 March 2025). https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-program-updates-type-1-diabetes-portfolio ↩ ↩2 ↩3 ↩4 ↩5

  6. Masson G. Vertex abandons islet cell-device combo after failing to improve diabetes biomarker. Fierce Biotech (2025). https://www.fiercebiotech.com/biotech/vertex-abandons-islet-cell-device-combo-after-it-failed-improve-diabetes-biomarker ↩

  7. Reichman TW, Markmann JF, Odorico J, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med (2025) 393:858-868. According to PubMed. https://doi.org/10.1056/NEJMoa2506549 ↩

  8. Hering BJ, Rickels MR, Bellin MD, et al. Advances in Cell Replacement Therapies for Diabetes. Diabetes (2025) 74:1068-1077. According to PubMed. https://doi.org/10.2337/db25-0037 ↩ ↩2

Coming soon

  • →Analysis of the explanted VX-264 devices to sharpen which failure mode dominated (oxygen/hypoxia vs. fibrosis)